Tracer library / [225Ac]Ac-hu11B6
[225Ac]Ac-hu11B6
Also written as [Ac-225]Ac-hu11B6; [Ac-225]hu11B6
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated monoclonal antibody (radioimmunoconjugate) targeting human kallikrein 2 (hK2)
- Target / mechanism
- Targets human kallikrein 2 (hK2), an androgen receptor gene product, delivering alpha-particle emitting Actinium-225 to AR-expressing tumor tissue PMID 30254080
- Clinical application
- Targeted alpha particle radioimmunotherapy of AR-expressing breast cancer, potentiated by androgen receptor activation PMID 30254080
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | 3.7% ± 2.1% | 99.3% ± 0.5% | DOTA-Bz-SCN Macrocyclics | 30254080 2019 Clin Cancer Res purified using a 2-step labeling procedure; protocol details are as previously published for this antibody - The radiochemical yield of [225Ac]hu11B6 is 3.7% ± 2.1% (mean ± SD, n = 13) |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- Macrocyclics
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [225Ac]Ac-hu11B6, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 30254080: 'S-2-(4-Isothiocyanatobenzyl)-1,4,7,10-tetraazacyclo-dodecane tetraacetic acid (DOTA-Bz-SCN, Macrocyclics, Inc.)'.